The Impact of TECAR Therapy on Athletes with Groin Pain
Study Overview
This study investigates how TECAR therapy affects pain, movement, strength, and the HAGOS questionnaire in athletes suffering from chronic adductor-related groin pain.
Background
Groin pain is a frequent problem for athletes, particularly due to adductor-related issues. Traditional treatments often fall short. TECAR therapy, which uses energy transfer, may offer a solution for these musculoskeletal conditions.
Study Design
The research was a randomized controlled trial involving 22 male professional athletes, averaging 21 years old. Participants were divided into two groups: one receiving real TECAR therapy and the other receiving a sham treatment. Both groups performed stretching exercises. The intervention group underwent 10 sessions of TECAR therapy, while the control group did not.
Key Findings
- Pain Reduction: Significant decreases in pain were observed in the TECAR group after 5 sessions, with even greater reductions after 10 sessions and one month later.
- Improved Range of Motion: The TECAR group showed notable improvements in hip adduction range of motion after one month.
- Other Outcomes: No significant differences were found in other measures of strength or function.
Conclusion
TECAR therapy appears effective in reducing pain and enhancing hip movement in athletes with groin pain.
Clinical Implications
Clinical trials like this are essential for developing effective treatments. Integrating findings into everyday practice is crucial. Our AI-driven platform, DocSym, consolidates clinical guidelines and research, making it easier for healthcare providers to access vital information.
Enhancing Patient Care
In today’s healthcare landscape, efficient operations are key. Our mobile applications facilitate scheduling, treatment monitoring, and telemedicine, streamlining patient management.
By leveraging AI, clinics can improve workflows, enhance patient outcomes, and reduce reliance on paper processes. Discover how we can assist you at aidevmd.com.